These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 33078716)

  • 1. Limiting tumor cells comprehensively at micro and macro levels to improve the therapeutic effect of chemotherapy.
    Wang B; Sun L; Zhao J; An J; Jin Y; Yang X; Li H; Zhang H; Zhang Z; Youmei A
    Nanotechnology; 2021 Jan; 32(1):015301. PubMed ID: 33078716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting actin inhibits repair of doxorubicin-induced DNA damage: a novel therapeutic approach for combination therapy.
    Pfitzer L; Moser C; Gegenfurtner F; Arner A; Foerster F; Atzberger C; Zisis T; Kubisch-Dohmen R; Busse J; Smith R; Timinszky G; Kalinina OV; Müller R; Wagner E; Vollmar AM; Zahler S
    Cell Death Dis; 2019 Apr; 10(4):302. PubMed ID: 30944311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel combination of TRAIL and doxorubicin enhances antitumor effect based on passive tumor-targeting of liposomes.
    Guo L; Fan L; Ren J; Pang Z; Ren Y; Li J; Wen Z; Jiang X
    Nanotechnology; 2011 Jul; 22(26):265105. PubMed ID: 21586819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the activities of actin-affecting drugs on tumor cell migration.
    Hayot C; Debeir O; Van Ham P; Van Damme M; Kiss R; Decaestecker C
    Toxicol Appl Pharmacol; 2006 Feb; 211(1):30-40. PubMed ID: 16005926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palmitoyl ascorbate and doxorubicin co-encapsulated liposome for synergistic anticancer therapy.
    Yang Y; Lu X; Liu Q; Dai Y; Zhu X; Wen Y; Xu J; Lu Y; Zhao D; Chen X; Li N
    Eur J Pharm Sci; 2017 Jul; 105():219-229. PubMed ID: 28526602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Dual pH-Responsive DOX-Encapsulated Liposome Combined with Glucose Administration Enhanced Therapeutic Efficacy of Chemotherapy for Cancer.
    Zhai L; Luo C; Gao H; Du S; Shi J; Wang F
    Int J Nanomedicine; 2021; 16():3185-3199. PubMed ID: 34007173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral Administration of Thermosensitive Hydrogel Co-Loaded with Norcantharidin Nanoparticles and Doxorubicin for the Treatment of Hepatocellular Carcinoma.
    Gao B; Luo J; Liu Y; Su S; Fu S; Yang X; Li B
    Int J Nanomedicine; 2021; 16():4073-4085. PubMed ID: 34163160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposome co-encapsulation of synergistic combination of irinotecan and doxorubicin for the treatment of intraperitoneally grown ovarian tumor xenograft.
    Shaikh IM; Tan KB; Chaudhury A; Liu Y; Tan BJ; Tan BM; Chiu GN
    J Control Release; 2013 Dec; 172(3):852-61. PubMed ID: 24459693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer.
    Feldmann G; Fendrich V; McGovern K; Bedja D; Bisht S; Alvarez H; Koorstra JB; Habbe N; Karikari C; Mullendore M; Gabrielson KL; Sharma R; Matsui W; Maitra A
    Mol Cancer Ther; 2008 Sep; 7(9):2725-35. PubMed ID: 18790753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substratum compliance regulates human trabecular meshwork cell behaviors and response to latrunculin B.
    Wood JA; McKee CT; Thomasy SM; Fischer ME; Shah NM; Murphy CJ; Russell P
    Invest Ophthalmol Vis Sci; 2011 Dec; 52(13):9298-303. PubMed ID: 22064990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway.
    Lu J; Liu X; Liao YP; Wang X; Ahmed A; Jiang W; Ji Y; Meng H; Nel AE
    ACS Nano; 2018 Nov; 12(11):11041-11061. PubMed ID: 30481959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxic tumor therapy by hemoglobin-mediated drug delivery and reversal of hypoxia-induced chemoresistance.
    Yang J; Li W; Luo L; Jiang M; Zhu C; Qin B; Yin H; Yuan X; Yin X; Zhang J; Luo Z; Du Y; You J
    Biomaterials; 2018 Nov; 182():145-156. PubMed ID: 30121013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octasulfate as drug trapping agent.
    Liu J; Chi D; Pan S; Zhao L; Wang X; Wang D; Wang Y
    Int J Pharm; 2019 Feb; 557():264-272. PubMed ID: 30599233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic inhibition of metastatic breast cancer by dual-chemotherapy with excipient-free rhein/DOX nanodispersions.
    Wang R; Yang Y; Yang M; Yuan D; Huang J; Chen R; Wang H; Hu L; Di L; Li J
    J Nanobiotechnology; 2020 Aug; 18(1):116. PubMed ID: 32847586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LyP-1-conjugated doxorubicin-loaded liposomes suppress lymphatic metastasis by inhibiting lymph node metastases and destroying tumor lymphatics.
    Yan Z; Zhan C; Wen Z; Feng L; Wang F; Liu Y; Yang X; Dong Q; Liu M; Lu W
    Nanotechnology; 2011 Oct; 22(41):415103. PubMed ID: 21914940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of cytoskeleton inhibitors on deadhesion kinetics of HepG2 cells on biomimetic surface.
    Feng Z; Chen B; Tang SC; Liao K; Chen WN; Chan V
    Colloids Surf B Biointerfaces; 2010 Jan; 75(1):67-74. PubMed ID: 19720507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering of cell microenvironment-responsive polypeptide nanovehicle co-encapsulating a synergistic combination of small molecules for effective chemotherapy in solid tumors.
    Ramasamy T; Ruttala HB; Chitrapriya N; Poudal BK; Choi JY; Kim ST; Youn YS; Ku SK; Choi HG; Yong CS; Kim JO
    Acta Biomater; 2017 Jan; 48():131-143. PubMed ID: 27794477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.
    Gao M; Xu Y; Qiu L
    J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Dynamics Simulation Reveal the Mechanism of Resistance of Mutant Actins to Latrunculin A - Insight into Specific Modifications to Design Novel Drugs to Overcome Resistance.
    Lalitha R; R PK; Mohammed MM
    Curr Comput Aided Drug Des; 2016; 12(2):107-18. PubMed ID: 27484118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-delivery of Doxorubicin and Curcumin with Polypeptide Nanocarrier for Synergistic Lymphoma Therapy.
    Guo W; Song Y; Song W; Liu Y; Liu Z; Zhang D; Tang Z; Bai O
    Sci Rep; 2020 May; 10(1):7832. PubMed ID: 32398729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.